Low-dose paclitaxel ameliorates renal fibrosis by suppressing transforming growth factor-β1-induced plasminogen activator inhibitor-1 signaling

Nephrology

Volumn 21, Issue 7, 2016, Pages 574-582

  Jung, Eun Sook ^a   Lee, Jeonghwan ^b   Heo, Nam Ju ^a   Kim, Sejoong ^a   Kim, Dong Ki ^a   Joo, Kwon Wook ^a   Han, Jin Suk ^a  

^a Seoul National University   (South Korea)

^b Hallym University   (South Korea)

Author keywords

fibrosis; mitogen activated protein kinases; paclitaxel; plasminogen activator inhibitor 1; smad proteins

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PERIODIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCHIFF BASE; SCLEROPROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLLAGEN METABOLISM; CONTROLLED STUDY; ENZYME ACTIVATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INNER MEDULLARY COLLECTING DUCT CELL; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY TUBULE DAMAGE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UNILATERAL URETERAL OBSTRUCTION; URETER OBSTRUCTION; WESTERN BLOTTING;

EID: 84976603749     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12747     Document Type: Article

References (28)

1. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J. Am. Soc. Nephrol. 2006; 17: 2999–3012.
2. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. Embo j. 1998; 17: 3091–100.
3. Guo B, Inoki K, Isono M et al. MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-beta in rat mesangial cells. Kidney Int. 2005; 68: 972–84.
4. Vayalil PK, Iles KE, Choi J, Yi AK, Postlethwait EM, Liu RM. Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007; 293: L1281–92.
5. Ganguly A, Yang H, Cabral F. Paclitaxel-dependent cell lines reveal a novel drug activity. Mol. Cancer Ther. 2010; 9: 2914–23.
6. Sengottuvel V, Leibinger M, Pfreimer M, Andreadaki A, Fischer D. Taxol facilitates axon regeneration in the mature CNS. J. Neurosci. 2011; 31: 2688–99.
7. Zhu S, Goldschmidt-Clermont PJ, Dong C. Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. Circ. Res. 2004; 94: 617–25.
8. Dong C, Li Z, Alvarez R Jr, Feng XH, Goldschmidt-Clermont PJ. Microtubule binding to Smads may regulate TGF beta activity. Mol. Cell 2000; 5: 27–34.
9. Zhou J, Zhong DW, Wang QW, Miao XY, Xu XD. Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity. World J. Gastroenterol. 2010; 16: 3330–4.
10. Wang C, Song X, Li Y et al. Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-beta1/Smad3 pathway via miR-140 upregulation. PLoS One 2013; 8: e70725.
11. Zhang D, Sun L, Xian W et al. Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Lab. Invest. 2010; 90: 436–47.
12. Sun L, Zhang D, Liu F et al. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J. Pathol. 2011; 225: 364–77.
13. Zhang L, Xu X, Yang R et al. Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling. Drug Des. Devel. Ther. 2015; 9: 2139–48.
14. Karbalay-Doust S, Noorafshan A, Pourshahid SM. Taxol and taurine protect the renal tissue of rats after unilateral ureteral obstruction: a stereological survey. Korean J Urol. 2012; 53: 360–7.
15. Butt MJ, Tarantal AF, Jimenez DF, Matsell DG. Collecting duct epithelial-mesenchymal transition in fetal urinary tract obstruction. Kidney Int. 2007; 72: 936–44.
16. Li J, Ariunbold U, Suhaimi N et al. Collecting duct-derived cells display mesenchymal stem cell properties and retain selective in vitro and in vivo epithelial capacity. J. Am. Soc. Nephrol. 2015; 26: 81–94.
17. Gong K, Xing D, Li P et al. cGMP inhibits TGF-beta signaling by sequestering Smad3 with cytosolic beta2-tubulin in pulmonary artery smooth muscle cells. Mol. Endocrinol. 2011; 25: 1794–803.
18. Tsukada T, Fushida S, Harada S et al. Low-dose paclitaxel modulates tumour fibrosis in gastric cancer. Int. J. Oncol. 2013; 42: 1167–74.
19. Pat B, Yang T, Kong C, Watters D, Johnson DW, Gobe G. Activation of ERK in renal fibrosis after unilateral ureteral obstruction: modulation by antioxidants. Kidney Int. 2005; 67: 931–43.
20. Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, Nikolic-Paterson DJ. The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J. Am. Soc. Nephrol. 2004; 15: 370–9.
21. Ma FY, Flanc RS, Tesch GH et al. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J. Am. Soc. Nephrol. 2007; 18: 472–84.
22. Ma FY, Liu J, Nikolic-Paterson DJ. The role of stress-activated protein kinase signaling in renal pathophysiology. Braz. J. Med. Biol. Res. 2009; 42: 29–37.
23. Masaki T, Foti R, Hill PA, Ikezumi Y, Atkins RC, Nikolic-Paterson DJ. Activation of the ERK pathway precedes tubular proliferation in the obstructed rat kidney. Kidney Int. 2003; 63: 1256–64.
24. Jang HS, Han SJ, Kim JI, Lee S, Lipschutz JH, Park KM. Activation of ERK accelerates repair of renal tubular epithelial cells, whereas it inhibits progression of fibrosis following ischemia/reperfusion injury. Biochim. Biophys. Acta 1832; 2013: 1998–2008.
25. Han Y, Masaki T, Hurst LA et al. Extracellular signal-regulated kinase-dependent interstitial macrophage proliferation in the obstructed mouse kidney. Nephrology (Carlton) 2008; 13: 411–8.
26. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 2005; 24: 5742–50.
27. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577–84.
28. Ventura JJ, Kennedy NJ, Flavell RA, Davis RJ. JNK regulates autocrine expression of TGF-beta1. Mol. Cell 2004; 15: 269–78.